Ecs Botanics Holdings Ltd

As of June 30, 2024, Ecs Botanics Holdings Ltd carries a market capitalization of 21.91M, placing it among publicly traded companies globally. Its enterprise value stands at 18.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ecs Botanics Holdings Ltd's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2024, Ecs Botanics Holdings Ltd has 1.29B shares outstanding.

As of June 30, 2024, Ecs Botanics Holdings Ltd trades at a trailing price-to-earnings ratio of 9.98. The price-to-sales ratio is 0.99, and the price-to-book ratio stands at 0.78.

As of June 30, 2024, Ecs Botanics Holdings Ltd trades at an EV/EBITDA multiple of 12.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 154.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 18.10M versus a market cap of 21.91M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Ecs Botanics Holdings Ltd maintains a current ratio of 4.58, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.63, indicating elevated leverage, while an interest coverage ratio of 23.29 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Ecs Botanics Holdings Ltd posted a return on equity (ROE) of 7.90, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 6.12, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 1.04 indicates how many times Ecs Botanics Holdings Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, Ecs Botanics Holdings Ltd recorded an income tax benefit of -70,388.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.92M, leaving 1.99M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ecs Botanics Holdings Ltd's stock has declined approximately 37.50% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2024, Ecs Botanics Holdings Ltd generated 20.03M in revenue and converted that into 1.99M in net income, yielding earnings per share of 0.00. EBITDA reached 1.44M, while operating income came in at 1.74M.

As of June 30, 2024, Ecs Botanics Holdings Ltd holds 4.82M in cash and equivalents against 1.02M in total debt, resulting in a net debt position of -3.16M. Total book value stands at 28.21M, with working capital of 15.39M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Ecs Botanics Holdings Ltd posted a gross margin of 45.60, reflecting its pricing power and cost economics. The operating margin of 8.68 and net profit margin of 9.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -20.51, meaning Ecs Botanics Holdings Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ecs Botanics Holdings Ltd's most recent stock split took place on May 18, 2017 with a 100:1 split ratio.

As of June 30, 2024, Ecs Botanics Holdings Ltd has an Altman Z-Score of 3.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.